Drugs / TAURODEOXYCHOLIC ACID
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06533878 | Sep 2023 → Dec 2024 overdue | dementia | Kukjeon Pharmaceutical Co.,Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT04255979 | Dec 2019 → Jun 2020 | infectious disease with sepsis | Shaperon | Completed | No outcome recorded |
| Phase 1 | NCT03492398 | Jan 2018 → Mar 2019 | atopic eczema | Shaperon | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04530643 | Aug 2020 → Sep 2021 | atopic eczema | Shaperon | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-24 | Shaperon | Results [보도자료] 샤페론, 누겔 글로벌 임상 2b상 결과 추가 분석 착수… “보습제 등 외부 요인 영향 가능성” shaperon.com ↗
수령한 결과에 따르면 누겔 투여군과 위약군 간 1차 평가지표 차이가 사전에 설정된 통계적 유의수준(양측성 0.025)을 충족하지 못한 것으로 확인됐다. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-24 | Shaperon | [보도자료] 샤페론, 누겔 글로벌 임상 2b상 결과 추가 분석 착수… “보습제 등 외부 요인 영향 가능성” shaperon.com ↗ |
| 2018-08-23 | Shaperon | [회사소식] [머니투데이] 샤페론, 염증완화 치료제 ‘HY209’와 항암체 치료제 ‘나노바디’로 주목 shaperon.com ↗ |
| 2018-08-22 | Shaperon | [회사소식] [머니투데이] 샤페론, 염증완화 치료제 ‘HY209’와 항암체 치료제 ‘나노바디’로 주목 shaperon.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAURODEOXYCHOLIC ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL412272 ↗ |
| Known as | Deoxycholyltaurine | ChEMBL registry synonym — accepted as the source's own label CHEMBL412272 ↗ |
| Known as | HY209 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04530643 ↗ |
| Known as | J339.140J | ChEMBL registry synonym — accepted as the source's own label CHEMBL412272 ↗ |
| Known as | Taurodesoxycholic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL412272 ↗ |
| Known as | Tudcabil | ChEMBL registry synonym — accepted as the source's own label CHEMBL412272 ↗ |
| Action | Activate | “The GPCR19 agonist, HY209” NCT03492398 ↗ |
| Modality | Small molecule | — CHEMBL412272 ↗ |
| Route | Intravenous | “after intravenous administration” NCT04255979 ↗ |
| Target | TNF | “inhibition of release of Tumor Necrosis Factor(TNF)-α” NCT06533878 ↗ |